Literature DB >> 10390151

Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

D Morrissey1, J O'Connell, D Lynch, G C O'Sullivan, F Shanahan, J K Collins.   

Abstract

Early metastasis contributes to the very poor prognosis of esophageal carcinoma. The recent immunohistochemical finding that invasive esophageal carcinomas express elevated levels of urokinase (uPA) and urokinase receptor (uPA-R) in vivo suggest that the plasminogen activation system may contribute to metastasis in esophageal cancer. The aim of our study was to functionally investigate, at the molecular level, the relative contribution of uPA and uPA-R to the invasiveness of esophageal cancer cells in vitro. The three esophageal cancer cell lines, OC1-3, generated in our laboratory, were analyzed for uPA and uPA-R expression by RT-PCR, immunoenzymatic staining, and quantitative ELISA. Invasiveness of all cell lines was quantified as percentage cellular invasiveness in a standardized Matrigel in vitro assay. OC1 and OC3, which were found to coexpress both uPA and uPA-R, displayed stronger invasiveness (44% and 32.5% respectively) relative to OC2 (19%) which expressed uPA-R but was negative for uPA. Transfection of OC2 cells with the uPA cDNA resulted in two variants, OC2.uPA1 and OC2.uPA2, stably expressing functional uPA. Both transfectants exhibited enhanced invasiveness (60% and 50% respectively) relative to the parent uPA-negative OC2 cells (19%). Antisense oligonucleotide inhibition of either uPA or uPA-R expression resulted in a similar, marked reduction in invasiveness of esophageal tumor cells which normally coexpress both molecules (OC1, OC3 and the uPA-expressing OC2-transfectant clones). Neither antisense treatment altered the basal invasiveness of OC2, which expresses uPA-R but not uPA. In conclusion, coexpression of uPA with its receptor, uPA-R, is required for functional involvement of the urokinase system in invasion by esophageal carcinoma cells. Our results suggest that these synergistic mediators of invasiveness are quantitatively major contributors to the invasiveness of esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390151     DOI: 10.1023/a:1026470417680

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  41 in total

1.  Ovarian plasminogen activator: relationship to ovulation and hormonal regulation.

Authors:  W H Beers; S Strickland; E Reich
Journal:  Cell       Date:  1975-11       Impact factor: 41.582

2.  Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue.

Authors:  L Ossowski; D Biegel; E Reich
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

3.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.

Authors:  Y Go; S K Chintala; S Mohanam; Z Gokaslan; B Venkaiah; R Bjerkvig; K Oka; G L Nicolson; R Sawaya; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.

Authors:  H Kobayashi; H Ohi; M Sugimura; H Shinohara; T Fujii; T Terao
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

5.  Plasminogen activators in oesophageal carcinoma.

Authors:  D F Hewin; P B Savage; D Alderson; M N Vipond
Journal:  Br J Surg       Date:  1996-08       Impact factor: 6.939

6.  Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.

Authors:  W Schlechte; M Brattain; D Boyd
Journal:  Cancer Commun       Date:  1990

7.  Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.

Authors:  K Karikó; A Kuo; D Boyd; S S Okada; D B Cines; E S Barnathan
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.

Authors:  O Wilhelm; U Weidle; S Höhl; P Rettenberger; M Schmitt; H Graeff
Journal:  FEBS Lett       Date:  1994-01-10       Impact factor: 4.124

9.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

Authors:  A L Roldan; M V Cubellis; M T Masucci; N Behrendt; L R Lund; K Danø; E Appella; F Blasi
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  4 in total

1.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.

Authors:  Hiroshi Kobayashi; Mika Suzuki; Naohiro Kanayama; Toshihiko Terao
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.

Authors:  Benjamin A Onwuegbusi; Jonathan R E Rees; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  PLoS One       Date:  2007-01-31       Impact factor: 3.240

4.  Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study.

Authors:  Julia Doulgere; Benjamin Otto; Maher Nassour; Gerrit Wolters-Eisfeld; Holger Rohde; Tim Magnus; Christoph Wagener; Thomas Streichert
Journal:  BMJ Open       Date:  2015-03-10       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.